Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00828841 is registered in ClinicalTrials.gov with Accelerated Community Oncology Research Network as lead sponsor.

NCT NCT00828841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00828841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Accelerated Community Oncology Research Network
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
August 31, 2012
Enrollment
601 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer